{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:02:47Z","timestamp":1789380167142,"version":"build-2803163510"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Study Objectives<\/jats:title>\n                    <jats:p>To evaluate the effect of daridorexant on nighttime respiratory function and sleep in adults with severe obstructive sleep apnea (OSA) without insomnia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This randomized, double-blind, placebo-controlled, two-period, crossover trial was conducted at a single sleep center in 16 adults (\u226518\u00a0years) with severe OSA without insomnia. In each period, daridorexant 50\u00a0mg or placebo was administered every evening for 5\u00a0days. Primary and secondary endpoints were the treatment differences (daridorexant\u2013placebo) for apnea\/hypopnea index (AHI) and oxygen saturation (SpO2) during total sleep time (TST), respectively, after last dosing. A mean increase in AHI \u226510 events\/h and mean decrease in nocturnal SpO2 \u2264\u20132% were the minimum changes considered to be clinically meaningful negative effects. Other endpoints included TST, latency to persistent sleep (LPS), and wake after sleep onset (WASO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean baseline AHI was 51.2 events\/h (range 30.8, 82.2) and mean SpO2 during TST was 92.1% (range 88.5, 94.3). No clinically meaningful effect of daridorexant on AHI or SpO2 during TST was detected. Treatment differences were\u2009\u22123.7 events\/h (one-sided 95% CI\u2009\u2264\u2009+4.2) and\u2009\u2212\u20090.12 % (one-sided 95% CI\u2009\u2265\u2009\u22120.6), respectively. Compared with placebo, daridorexant increased TST by 32.5\u00a0min (90% CI: 6.9, 58.2), associated with shorter LPS (\u221210.3\u00a0min [90% CI: \u221220.6, \u22120.02]) and a trend towards reduced WASO (\u221215.2\u00a0min [\u221231.2, 0.9]). Four adverse events were reported (daridorexant n\u2009=\u20093; placebo n\u2009=\u20091), all of mild intensity and none related to respiratory function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Short-term treatment with daridorexant does not impair sleep-disordered breathing and may improve sleep in patients with severe OSA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/study\/NCT05458193, NCT05458193.<\/jats:p>\n                    <jats:p>Statement of Significance Obstructive sleep apnea (OSA) is highly prevalent and associated, in 30%-50% of cases, with insomnia-related symptoms, yet the safety of insomnia medications in OSA remains unclear. Daridorexant, a dual orexin receptor antagonist for the treatment of adults with insomnia disorder, previously showed no negative effect on sleep-disordered breathing in participants with mild\/moderate OSA. This randomized, double-blind, placebo-controlled, crossover trial evaluates daridorexant 50\u00a0mg (maximum therapeutic dose) in participants with severe OSA without insomnia. Repeated dosing (5 nights) did not impair nighttime respiratory function, as assessed by apnea\/hypopnea index and nocturnal oxygen saturation. Moreover, improvements in sleep characteristics were observed with daridorexant, extending evidence that daridorexant 50\u00a0mg is safe and well-tolerated and may improve sleep in adults with severe OSA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/sleep\/zsag145","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:42:42Z","timestamp":1779363762000},"source":"Crossref","is-referenced-by-count":0,"title":["Daridorexant in severe obstructive sleep apnea: effects on sleep-disordered breathing and sleep"],"prefix":"10.1093","volume":"49","author":[{"given":"Ingo","family":"Fietze","sequence":"first","affiliation":[{"name":"Center of Sleep Medicine, Charite\u2013Universit\u00e4tsmedizin Berlin , Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6734-5674","authenticated-orcid":false,"given":"Marie-Laure","family":"Boof","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd , Allschwil , Basel-Landschaft,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2281-6153","authenticated-orcid":false,"given":"Katharina","family":"Lederer","sequence":"additional","affiliation":[{"name":"Advanced Sleep Research GmbH , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Lemoine","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd , Allschwil , Basel-Landschaft,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Vaillant","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd , Allschwil , Basel-Landschaft,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3832-2358","authenticated-orcid":false,"given":"Jean-Louis","family":"P\u00e9pin","sequence":"additional","affiliation":[{"name":"HP2 Laboratory, INSERM U1300, Grenoble Alpes University Hospital and EFCR Laboratory , Thorax and Vessels Division, Grenoble ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"1","key":"2026091405070016700_ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.15","article-title":"Obstructive sleep apnoea syndrome","volume":"1","author":"L\u00e9vy","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"2026091405070016700_ref2","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/s2213-2600(25)00243-7","article-title":"Projecting the 30-year burden of obstructive sleep apnoea in the USA: a prospective modelling study","volume":"13","author":"Boers","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"8","key":"2026091405070016700_ref3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/s2213-2600(19)30198-5","article-title":"Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis","volume":"7","author":"Benjafield","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"5","key":"2026091405070016700_ref4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.sleep.2009.10.005","article-title":"Obstructive sleep apnea syndrome in the Sao Paulo Epidemiologic Sleep Study","volume":"11","author":"Tufik","year":"2010","journal-title":"Sleep Med"},{"issue":"2","key":"2026091405070016700_ref5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/life13020387","article-title":"A scoping review of sleep apnea: where do we stand?","volume":"13","author":"Hirani","year":"2023","journal-title":"Life (Basel)"},{"issue":"3","key":"2026091405070016700_ref6","doi-asserted-by":"publisher","first-page":"835","DOI":"10.5664\/jcsm.9738","article-title":"Facilitators and barriers to getting obstructive sleep apnea diagnosed: perspectives from patients and their partners","volume":"18","author":"Ye","year":"2022","journal-title":"J Clin Sleep Med"},{"issue":"6","key":"2026091405070016700_ref7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/mcp.0000000000001007","article-title":"Co-morbid insomnia and sleep apnea (COMISA): recent research and future directions","volume":"29","author":"Sweetman","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"2026091405070016700_ref8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.smrv.2019.01.004","article-title":"Worldwide and regional prevalence rates of co-occurrence of insomnia and insomnia symptoms with obstructive sleep apnea: a systematic review and meta-analysis","volume":"45","author":"Zhang","year":"2019","journal-title":"Sleep Med Rev"},{"key":"2026091405070016700_ref9","doi-asserted-by":"publisher","first-page":"101519","DOI":"10.1016\/j.smrv.2021.101519","article-title":"Bi-directional relationships between co-morbid insomnia and sleep apnea (COMISA)","volume":"60","author":"Sweetman","year":"2021","journal-title":"Sleep Med Rev"},{"issue":"17","key":"2026091405070016700_ref10","doi-asserted-by":"publisher","first-page":"9248","DOI":"10.3390\/ijerph18179248","article-title":"Comorbid insomnia and obstructive sleep apnea (COMISA): current concepts of patient management","volume":"18","author":"Ragnoli","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"2026091405070016700_ref11","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.rmed.2005.10.002","article-title":"Clinical co-morbidities in obstructive sleep apnea syndrome treated with mandibular repositioning appliance","volume":"100","author":"Machado","year":"2006","journal-title":"Respir Med"},{"issue":"8","key":"2026091405070016700_ref12","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.sleep.2010.03.012","article-title":"Sleep maintenance insomnia complaints predict poor CPAP adherence: a clinical case series","volume":"11","author":"Wickwire","year":"2010","journal-title":"Sleep Med"},{"issue":"12","key":"2026091405070016700_ref13","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.5665\/sleep.3226","article-title":"Symptoms of insomnia among patients with obstructive sleep apnea before and after two years of positive airway pressure treatment","volume":"36","author":"Bjornsdottir","year":"2013","journal-title":"Sleep."},{"issue":"25","key":"2026091405070016700_ref14","doi-asserted-by":"publisher","first-page":"05383","DOI":"10.1016\/j.chest.2025.08.044","article-title":"Positive airway pressure therapy use and health care resource use in patients with OSA and comorbid insomnia","volume":"S0012-3692","author":"Cole","year":"2025","journal-title":"Chest."},{"issue":"13","key":"2026091405070016700_ref15","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.jacc.2024.07.024","article-title":"Treatment of OSA and its impact on cardiovascular disease, part 2: JACC state-of-the-art review","volume":"84","author":"Javaheri","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2026091405070016700_ref16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","article-title":"Daridorexant: first approval","volume":"82","author":"Markham","year":"2022","journal-title":"Drugs."},{"issue":"6","key":"2026091405070016700_ref17","doi-asserted-by":"publisher","first-page":"zsaa275","DOI":"10.1093\/sleep\/zsaa275","article-title":"Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea","volume":"44","author":"Boof","year":"2020","journal-title":"Sleep."},{"key":"2026091405070016700_ref18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.sleep.2021.11.015","article-title":"Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apnea","volume":"92","author":"Boof","year":"2022","journal-title":"Sleep Med"},{"issue":"4","key":"2026091405070016700_ref19","doi-asserted-by":"publisher","first-page":"e13248","DOI":"10.1111\/jsr.13248","article-title":"Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease","volume":"30","author":"Boof","year":"2021","journal-title":"J Sleep Res"},{"issue":"3","key":"2026091405070016700_ref20","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/0269881119882854","article-title":"Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration","volume":"34","author":"Muehlan","year":"2020","journal-title":"J Psychopharmacol"},{"issue":"2","key":"2026091405070016700_ref21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/jcp.0000000000001182","article-title":"Pharmacokinetics and pharmacodynamics of the dual orexin receptor antagonist daridorexant in Japanese and Caucasian subjects","volume":"40","author":"Muehlan","year":"2020","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"2026091405070016700_ref22","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.euroneuro.2019.05.009","article-title":"Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration","volume":"29","author":"Muehlan","year":"2019","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"2026091405070016700_ref23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5664\/jcsm.10788","article-title":"A randomized, double-blind, placebo-controlled, crossover study of respiratory safety of lemborexant in moderate to severe obstructive sleep apnea","volume":"20","author":"Cheng","year":"2024","journal-title":"J Clin Sleep Med"},{"issue":"1","key":"2026091405070016700_ref24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5664\/jcsm.5382","article-title":"Effects of suvorexant, an orexin receptor antagonist, on respiration during sleep in patients with obstructive sleep apnea","volume":"12","author":"Sun","year":"2016","journal-title":"J Clin Sleep Med"},{"issue":"5","key":"2026091405070016700_ref25","first-page":"667","article-title":"The report of an American Academy of Sleep Medicine Task Force","volume":"22","author":"Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research","year":"1999","journal-title":"Sleep."},{"issue":"12","key":"2026091405070016700_ref26","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa041832","article-title":"Day-night pattern of sudden death in obstructive sleep apnea","volume":"352","author":"Gami","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"2026091405070016700_ref27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","article-title":"Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials","volume":"21","author":"Mignot","year":"2022","journal-title":"Lancet Neurol"},{"issue":"171","key":"2026091405070016700_ref28","doi-asserted-by":"publisher","first-page":"230166","DOI":"10.1183\/16000617.0166-2023","article-title":"REM sleep obstructive sleep apnoea","volume":"33","author":"Bonsignore","year":"2024","journal-title":"Eur Respir Rev"},{"issue":"2-3","key":"2026091405070016700_ref29","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.psychres.2012.07.045","article-title":"Is a one-night stay in the lab really enough to conclude? First-night effect and night-to-night variability in polysomnographic recordings among different clinical population samples","volume":"200","author":"Newell","year":"2012","journal-title":"Psychiatry Res"},{"issue":"7","key":"2026091405070016700_ref30","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40263-023-01020-9","article-title":"Number, duration, and distribution of wake bouts in patients with insomnia disorder: effect of daridorexant and zolpidem","volume":"37","author":"Di Marco","year":"2023","journal-title":"CNS Drugs"},{"issue":"2","key":"2026091405070016700_ref31","doi-asserted-by":"publisher","first-page":"e70135","DOI":"10.1111\/jsr.70135","article-title":"The effects of daridorexant on patients with comorbid insomnia disorder and untreated mild obstructive sleep apnoea: a post hoc subgroup analysis of a phase 3, randomised clinical trial","volume":"35","author":"Lettieri","year":"2026","journal-title":"J Sleep Res"},{"issue":"10","key":"2026091405070016700_ref32","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.5664\/jcsm.9378","article-title":"The prevalence and comorbidities of obstructive sleep apnea in middle-aged men and women: the Busselton Healthy Ageing Study","volume":"17","author":"Cunningham","year":"2021","journal-title":"J Clin Sleep Med"},{"issue":"9","key":"2026091405070016700_ref33","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.5664\/jcsm.9300","article-title":"Night-to-night variability in obstructive sleep apnea using peripheral arterial tonometry: a case for multiple night testing","volume":"17","author":"Tschopp","year":"2021","journal-title":"J Clin Sleep Med"}],"container-title":["SLEEP"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/sleep\/advance-article-pdf\/doi\/10.1093\/sleep\/zsag145\/68368306\/zsag145.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/49\/9\/zsag145\/68368306\/zsag145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/49\/9\/zsag145\/68368306\/zsag145.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:07:09Z","timestamp":1789376829000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/sleep\/article\/doi\/10.1093\/sleep\/zsag145\/8690624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5,22]]},"published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/sleep\/zsag145","relation":{},"ISSN":["0161-8105","1550-9109"],"issn-type":[{"value":"0161-8105","type":"print"},{"value":"1550-9109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,5,22]]},"article-number":"zsag145"}}